Superior Court Approves $2.5 Million Risperdal Verdict
Superior Court Approves $2.5 Million Risperdal Verdict

Introduction
On October 31, 2018, a unanimous three-judge panel in the Pennsylvania Superior Court upheld the $2.5 million Risperdal verdict awarded to an Alabama boy, who developed breasts due to the antipsychotic drug.
The case was the first among thousands of other product liability lawsuits filed against J&J. In August 2015, J&J appealed to overturn the verdict awarded to the plaintiff. The plaintiff was on Risperdal to treat his autism-related behavioral issues, and his parents claimed his abnormal breast growth was the result of the drug's side effect.
More than 7,000 Risperdal product liability lawsuits against J&J are filed in the Pennsylvania State Court. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).
Latest News
Cencora Directors Settle Opioid Oversight Case for $111M
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…
Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients
A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…
FDA Adds New Warnings on Long-Term Opioid Risks
Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.
…